Jazz Pharmaceuticals plc (JAZZ) Financial Ratios
21 years of historical data (2005–2025) · Healthcare · Biotechnology
EV/EBITDA
↑
23.65
↑+43% vs avg
5yr avg: 16.57
30Y Low8.6·High33.1
P/FCF
↓
10.87
+19% vs avg
5yr avg: 9.11
30Y Low6.0·High61.5
P/B Ratio
↑
3.17
↑+33% vs avg
5yr avg: 2.38
30Y Low1.9·High25.4
ROE
↑
-8.5%
↑-1504% vs avg
5yr avg: 0.6%
30Y Low-252%·High112%
Debt/EBITDA
↓
7.08
+1% vs avg
5yr avg: 7.03
30Y Low0.7·High10.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
JAZZ Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Jazz Pharmaceuticals plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 10.9x P/FCF, 19% above the 5-year average of 9.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14.1B | $10.4B | $8.1B | $8.9B | $10.0B | $7.6B | $9.3B | $8.6B | $7.6B | $8.3B | $6.7B |
| Enterprise Value | $18.1B | $14.4B | $11.9B | $13.1B | $14.9B | $13.2B | $10.5B | $9.7B | $8.9B | $9.5B | $8.4B |
| P/E Ratio → | -38.47 | — | 14.24 | 20.16 | — | — | 39.11 | 16.42 | 16.98 | 16.92 | 17.01 |
| P/S Ratio | 3.30 | 2.43 | 2.00 | 2.31 | 2.72 | 2.46 | 3.95 | 3.97 | 4.01 | 5.10 | 4.53 |
| P/B Ratio | 3.17 | 2.40 | 1.99 | 2.37 | 3.23 | 1.92 | 2.55 | 2.76 | 2.75 | 3.04 | 3.59 |
| P/FCF | 10.87 | 7.99 | 6.03 | 8.30 | 12.88 | 10.38 | 17.93 | 14.46 | 11.37 | 14.26 | 16.49 |
| P/OCF | 10.40 | 7.65 | 5.82 | 8.12 | 7.83 | 9.77 | 10.37 | 11.07 | 9.50 | 11.91 | 11.42 |
P/E links to full P/E history page with 30-year chart
JAZZ EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Jazz Pharmaceuticals plc's enterprise value stands at 23.7x EBITDA, 43% above its 5-year average of 16.6x. The Healthcare sector median is 14.2x, placing the stock at a 66% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.37 | 2.92 | 3.43 | 4.07 | 4.26 | 4.45 | 4.50 | 4.69 | 5.84 | 5.65 |
| EV / EBITDA | 23.65 | 18.79 | 8.63 | 10.80 | 26.41 | 18.22 | 16.03 | 10.78 | 10.67 | 13.62 | 11.92 |
| EV / EBIT | 80.77 | — | 13.79 | 16.22 | 17.75 | 27.70 | 13.74 | 15.14 | 12.40 | 15.40 | 13.14 |
| EV / FCF | — | 11.10 | 8.81 | 12.31 | 19.25 | 17.96 | 20.21 | 16.37 | 13.30 | 16.32 | 20.56 |
JAZZ Profitability
Margins and return-on-capital ratios measuring operating efficiency
Jazz Pharmaceuticals plc earns an operating margin of 5.3%. Operating margins have compressed from 15.1% to 5.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -8.5% indicates the company is currently destroying shareholder equity. ROIC of 2.1% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.2% | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | 93.7% | 94.1% | 93.6% | 93.2% | 92.9% |
| Operating Margin | 5.3% | 5.3% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% | 24.6% | 32.5% | 32.7% | 39.8% |
| Net Profit Margin | -8.3% | -8.3% | 13.8% | 10.8% | -6.1% | -10.6% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.5% | -8.5% | 14.3% | 12.2% | -6.4% | -8.6% | 7.0% | 17.8% | 16.3% | 21.3% | 22.8% |
| ROA | -3.0% | -3.0% | 4.8% | 3.7% | -1.9% | -3.5% | 4.0% | 9.7% | 8.7% | 9.8% | 9.7% |
| ROIC | 2.1% | 2.1% | 6.8% | 5.4% | -0.6% | 1.8% | 6.2% | 9.6% | 11.6% | 10.6% | 16.6% |
| ROCE | 2.2% | 2.2% | 6.9% | 5.9% | -0.6% | 2.0% | 6.8% | 10.6% | 12.7% | 11.3% | 15.4% |
JAZZ Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Jazz Pharmaceuticals plc carries a Debt/EBITDA ratio of 7.1x, which is highly leveraged (120% above the sector average of 3.2x). Net debt stands at $4.0B ($5.4B total debt minus $1.4B cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.26 | 1.26 | 1.51 | 1.55 | 1.88 | 1.55 | 0.61 | 0.57 | 0.58 | 0.58 | 1.08 |
| Debt / EBITDA | 7.08 | 7.08 | 4.48 | 4.76 | 10.31 | 8.51 | 3.43 | 1.96 | 1.92 | 2.28 | 2.88 |
| Net Debt / Equity | — | 0.93 | 0.92 | 1.15 | 1.60 | 1.40 | 0.33 | 0.36 | 0.47 | 0.44 | 0.89 |
| Net Debt / EBITDA | 5.26 | 5.26 | 2.72 | 3.52 | 8.74 | 7.69 | 1.82 | 1.26 | 1.55 | 1.72 | 2.36 |
| Debt / FCF | — | 3.11 | 2.78 | 4.01 | 6.37 | 7.59 | 2.29 | 1.91 | 1.93 | 2.06 | 4.07 |
| Interest Coverage | -2.22 | -2.22 | 3.62 | 2.80 | 2.91 | 1.70 | 7.68 | 8.89 | 9.12 | 7.89 | 10.33 |
JAZZ Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.86x means Jazz Pharmaceuticals plc can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.24x to 1.86x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | 1.86 | 4.46 | 2.24 | 2.79 | 3.23 | 4.34 | 4.47 | 3.57 | 3.29 | 2.91 |
| Quick Ratio | 1.67 | 1.67 | 3.99 | 1.85 | 2.03 | 1.90 | 4.20 | 4.26 | 3.42 | 3.15 | 2.77 |
| Cash Ratio | 1.09 | 1.09 | 2.88 | 1.06 | 0.94 | 0.73 | 3.26 | 2.96 | 2.39 | 2.04 | 1.65 |
| Asset Turnover | — | 0.37 | 0.34 | 0.34 | 0.34 | 0.25 | 0.36 | 0.39 | 0.36 | 0.32 | 0.31 |
| Inventory Turnover | 1.21 | 1.21 | 0.93 | 0.73 | 0.76 | 0.41 | 1.56 | 1.63 | 2.30 | 2.55 | 3.09 |
| Days Sales Outstanding | — | 71.05 | 64.30 | 67.19 | 64.98 | 66.45 | 61.23 | 60.11 | 50.93 | 50.54 | 57.46 |
JAZZ Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Jazz Pharmaceuticals plc returns 0.9% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 7.0% | 5.0% | — | — | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% |
| FCF Yield | 9.2% | 12.5% | 16.6% | 12.0% | 7.8% | 9.6% | 5.6% | 6.9% | 8.8% | 7.0% | 6.1% |
| Buyback Yield | 0.9% | 1.2% | 3.8% | 3.0% | 0.0% | 0.0% | 1.6% | 3.5% | 6.9% | 1.2% | 4.1% |
| Total Shareholder Yield | 0.9% | 1.2% | 3.8% | 3.0% | 0.0% | 0.0% | 1.6% | 3.5% | 6.9% | 1.2% | 4.1% |
| Shares Outstanding | — | $61M | $66M | $72M | $63M | $60M | $57M | $58M | $61M | $61M | $62M |
Peer Comparison
Compare JAZZ with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 JAZZYou | $14B | -38.5 | 23.7 | 10.9 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 SUPN | $3B | -65.3 | 45.1 | 55.6 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PCRX | $878M | 139.6 | 9.4 | 6.4 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AVNS | $1B | -17.1 | — | 27.1 | 49.8% | -8.8% | -8.5% | -5.4% | — |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 ALKS | $7B | 31.5 | 22.9 | 15.6 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 INCY | $20B | 15.3 | 11.6 | 14.5 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 HALO | $8B | 26.8 | 11.2 | 12.6 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 AVPT | $2B | 69.4 | 44.2 | 27.1 | 74.1% | 7.9% | 9.4% | 1143.3% | 0.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 21 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into JAZZ consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
JAZZ — Frequently Asked Questions
Quick answers to the most common questions about buying JAZZ stock.
What is Jazz Pharmaceuticals plc's P/E ratio?
Jazz Pharmaceuticals plc's current P/E ratio is -38.5x. The historical average is 33.0x.
What is Jazz Pharmaceuticals plc's EV/EBITDA?
Jazz Pharmaceuticals plc's current EV/EBITDA is 23.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.4x.
What is Jazz Pharmaceuticals plc's ROE?
Jazz Pharmaceuticals plc's return on equity (ROE) is -8.5%. The historical average is 8.4%.
Is JAZZ stock overvalued?
Based on historical data, Jazz Pharmaceuticals plc is trading at a P/E of -38.5x. Compare with industry peers and growth rates for a complete picture.
What are Jazz Pharmaceuticals plc's profit margins?
Jazz Pharmaceuticals plc has 88.2% gross margin and 5.3% operating margin.
How much debt does Jazz Pharmaceuticals plc have?
Jazz Pharmaceuticals plc's Debt/EBITDA ratio is 7.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.